MUC5B genotype affects survival of patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment

D. Biondini (Padova, Italy), E. Balestro (Padova, Italy), C. Rigobello (Padova, Italy), S. Baraldo (Padova, Italy), D. Lacedonia (Foggia, Italy), E. Cocconcelli (Padova, Italy), E. Bazzan (Padova, Italy), M. Foschino Barbaro (Foggia, Italy), M. Cosio (Montreal, Canada), M. Saetta (Padova, Italy), P. Spagnolo (Padova, Italy)

Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia
Session: Treatment and prognosis of idiopathic interstitial pneumonia
Session type: Thematic Poster
Number: 1352
Disease area: Interstitial lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Biondini (Padova, Italy), E. Balestro (Padova, Italy), C. Rigobello (Padova, Italy), S. Baraldo (Padova, Italy), D. Lacedonia (Foggia, Italy), E. Cocconcelli (Padova, Italy), E. Bazzan (Padova, Italy), M. Foschino Barbaro (Foggia, Italy), M. Cosio (Montreal, Canada), M. Saetta (Padova, Italy), P. Spagnolo (Padova, Italy). MUC5B genotype affects survival of patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment. 1352

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
IL8 as a marker of severity of disease progression in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2007; 30: Suppl. 51, 373s
Year: 2007

Warfarin and survival in people with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2007; 30: Suppl. 51, 246s
Year: 2007

The long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012

Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment
Source: International Congress 2016 – IPF treatment I
Year: 2016


Changes in biomarkers in patients with idiopathic pulmonary fibrosis (IPF) treated with nintedanib and sildenafil
Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia
Year: 2019



Are there differences in response to pulmonary rehabilitation (PR) in idiopathic pulmonary fibrosis (IPF) and COPD patients?
Source: International Congress 2017 – New insights into pulmonary rehabilitation in patients with chronic lung diseases
Year: 2017

Effect of MUC5B gene polymorphism on survival in a Lebanese population of patients with idiopathic pulmonary fibrosis
Source: International Congress 2018 – Pitfalls in the diagnosis and management of rare diffuse parenchymal lung diseases (DPLDs)
Year: 2018

Neutrophil-rich inflammation in induced sputum of patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2001; 18: Suppl. 33, 409s
Year: 2001

Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases
Year: 2013


Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017


Bosentan in idiopathic pulmonary fibrosis (IPF): quality of life (QOL) results of the BUILD 1 study
Source: Annual Congress 2006 - Quality of life in various respiratory diseases
Year: 2006


Effect of low dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): results from a real life study
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021


Polymorphism of the genes of xenobiothics detoxification in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2004; 24: Suppl. 48, 536s
Year: 2004

Association between MUC5B rs35705950 genotype and response to antifibrotic treatment in patients with Idiopathic Pulmonary Fibrosis (IPF).
Source: Virtual Congress 2020 – Biomarkers and mechanistic aspects of idiopathic pulmonary fibrosis
Year: 2020


Association between AGTTGFB1ESR1, and VDR gene variants with idiopathic pulmonary fibrosis (IPF) and pulmonary sarcoidosis (PS) clinical features
Source: International Congress 2017 – Functional genomics knowledge in parenchymal and bronchial diseases
Year: 2017




Does IFN-g slow progression of idiopathic pulmonary fibrosis (IPF)?
Source: Eur Respir J 2005; 26: Suppl. 49, 335s
Year: 2005

Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012


A cohort of patients with a progressive fibrosing phenotype of interstitial lung disease (PF-ILD) other than idiopathic pulmonary fibrosis (IPF): the PROGRESS study
Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Year: 2020


MUC5B gene in a cohort of Lebanese patients with idiopathic pulmonary fibrosis
Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia
Year: 2018

Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012